Baral Harapriya, Kaundal Ravinder K
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow, UP 226002, India.
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Raebareli (NIPER-R), Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow, UP 226002, India.
Cytokine Growth Factor Rev. 2025 Jun;83:18-34. doi: 10.1016/j.cytogfr.2025.03.001. Epub 2025 Mar 22.
Traumatic brain injury (TBI) is a major global health concern and a leading cause of morbidity and mortality. Neuroinflammation is a pivotal driver of both the acute and chronic phases of TBI, with pattern recognition receptors (PRRs) playing a central role in detecting damage-associated molecular patterns (DAMPs) and initiating immune responses. Key PRR subclasses, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and cGAS-like receptors (cGLRs), are abundantly expressed in central nervous system (CNS) cells and infiltrating immune cells, where they mediate immune activation, amplify neuroinflammatory cascades, and exacerbate secondary injury mechanisms. This review provides a comprehensive analysis of these PRR subclasses, detailing their distinct structural characteristics, expression patterns, and roles in post-TBI immune responses. We critically examine the molecular mechanisms underlying PRR-mediated signaling and explore their contributions to neuroinflammatory pathways and secondary injury processes. Additionally, preclinical and clinical evidence supporting the therapeutic potential of targeting PRRs to mitigate neuroinflammation and improve neurological outcomes is discussed. By integrating recent advancements, this review offers an in-depth understanding of the role of PRRs in TBI pathobiology and underscores the potential of PRR-targeted therapies in mitigating TBI-associated neurological deficits.
创伤性脑损伤(TBI)是一个重大的全球健康问题,也是发病和死亡的主要原因。神经炎症是TBI急性和慢性阶段的关键驱动因素,模式识别受体(PRR)在检测损伤相关分子模式(DAMP)和启动免疫反应中起核心作用。关键的PRR亚类,包括Toll样受体(TLR)、NOD样受体(NLR)和cGAS样受体(cGLR),在中枢神经系统(CNS)细胞和浸润性免疫细胞中大量表达,它们在其中介导免疫激活、放大神经炎症级联反应并加剧继发性损伤机制。本综述对这些PRR亚类进行了全面分析,详细阐述了它们独特的结构特征、表达模式以及在TBI后免疫反应中的作用。我们批判性地研究了PRR介导信号传导的分子机制,并探讨了它们对神经炎症途径和继发性损伤过程的贡献。此外,还讨论了支持靶向PRR以减轻神经炎症和改善神经学结果的治疗潜力的临床前和临床证据。通过整合最新进展,本综述深入了解了PRR在TBI病理生物学中的作用,并强调了PRR靶向治疗在减轻TBI相关神经功能缺损方面的潜力。